All In Biotech

Free tool

FAERS Monitor: Verquvo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214377 or its brand name (Verquvo, Vericiguat). Reports on generic versions are filed under their own applications.

Reports

994

Serious

510

51% of reports

Hospitalization

259

Death reported

152

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hypotension116
  • death98
  • cardiac failure77
  • dizziness69
  • product dose omission issue55
  • no adverse event49
  • blood pressure decreased43
  • anaemia40
  • fatigue37
  • dyspnoea36
  • malaise34
  • nausea31
  • product use issue30
  • asthenia29
  • diarrhoea29

Reports by year received

View as table
YearReports
20172
20183
2021114
2022218
2023213
2024177
2025181
202686

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,165 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cardiac failureSignal7720.316.41,399
blood pressure decreasedSignal4313.710.2495
hypotensionSignal11612.210.31,197
no adverse eventSignal495.74.4188
anaemiaSignal404.43.3104
product dose omission issueSignal554.03.1120
product use issueSignal303.42.448
dizzinessSignal692.92.388
deathSignal982.42.083
malaise341.61.28
asthenia291.61.17
dyspnoea361.31.03
fatigue371.00.70
diarrhoea291.00.70
nausea310.80.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.